Financial Results, Regulatory Approvals, Stock Price Movements and Strategic Collaborations - Research Report on Pfizer, Stryker, Agilent Technologies, Celldex Therapeutics, and Novo Nordisk Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, October 23, 2013 NEW YORK, October 23, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Stryker Corporation (NYSE: SYK), Agilent Technologies Inc. (NYSE: A), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Novo Nordisk A/S (ADR) (NYSE: NVO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On October 18, 2013, Bloomberg reported that authorities from Switzerland seized more than 1 million fake Pfizer Inc. (Pfizer) Xanax anti-anxiety pills at the Zurich airport. According to the Bloomberg report, Swissmedic - Switzerland's drug regulator, said in a statement that four crates weighing more than 400 kilograms (880 pounds) were intercepted while being transported from China to Egypt and were ordered to be destroyed after tests determined that the pills contained no active ingredients. In addition, Swissmedic said that it informed authorities abroad of the discovery, particularly in China and in Egypt, and that no patients in Switzerland will be affected. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE] -- Stryker Corporation Research Report On October 17, 2013, Stryker Corporation (Stryker) reported its Q3 2013 results. The Company's net sales increased 4.8% YoY to $2.2 billion during the quarter. Net earnings were $103 million or $0.27 per diluted share in Q3 2013 compared to net earnings of $353 million or $0.92 per diluted share in Q3 2012. Commenting on the results, Kevin A. Lobo, President and CEO of Stryker, said, "We are pleased with our strong third quarter sales growth of 6.8% in constant currency, and 6.1% excluding currency and acquisitions. We believe these results not only represent gradual improvement in our key markets but also underscore our commitment to delivering above market growth. We are on track to meet our full year adjusted EPS guidance of $4.20 to $4.26." The Full Research Report on Stryker Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5b34_SYK] -- Agilent Technologies Inc. Research Report On October 16, 2013, Agilent Technologies Inc. (Agilent Technologies) and Seoul National University Hospital announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers. Agilent Technologies said that under the agreement, the hospital's Department of Laboratory Medicine will use the Agilent 6460 Triple Quadrupole LC/MS system as well as Agilent Technologies' support services and application expertise. Agilent Technologies added that the hospital is committed to creating and maintaining an optimal environment for new biomarkers to be identified and tested rigorously by highly sensitive yet robust instruments. Rod Minett, Agilent Technologies' General Manager, Life Sciences, South Korea and the South Asia-Pacific region, said, "We are privileged to partner with Seoul National University Hospital, which has a strong tradition of innovation and quality care for customers. Through this collaboration, we hope to establish more effective and varied verifications system for the medical and life sciences industries." The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/075e_A] -- Celldex Therapeutics Inc. Research Report On October 18, 2013, Celldex Therapeutics Inc.'s (Celldex Therapeutics) stock declined 4.44%, ending the day at $25.80. Over the previous three trading sessions, shares of Celldex Therapeutics declined 1.49% compared to the Nasdaq Composite, which gained 3.17% during the same period. The Full Research Report on Celldex Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b443_CLDX] -- Novo Nordisk A/S (ADR) Research Report On October 16, 2013, Novo Nordisk A/S (ADR) (Novo Nordisk) announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics License Application (BLA) for recombinant coagulation favor VIII, Novoeight. The Company said that the FDA approved Novoeight for use in adults and children with haemophilia A for: control and prevention of bleeding; perioperative management; and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, said, "The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A, and demonstrates our commitment to haemophilia." Novo Nordisk plans to launch Novoeight in the U.S. shortly after April 2015, following the expiration of its existing patents. The Full Research Report on Novo Nordisk A/S (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fee1_NVO] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Financial Results, Regulatory Approvals, Stock Price Movements and Strategic Collaborations - Research Report on Pfizer,
Press spacebar to pause and continue. Press esc to stop.